Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcar...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 3.0% | ||
| P/E Ratio | 27.9x | ||
| Revenue | 88.821 B | ||
| Net Income to Company | 14.066 B |
| JNJ | Peers | Sector | |
|---|---|---|---|
Market Cap | 395.8 B | 37.716 B | 66.246 M |
Price % of 52 Week High | 95.8% | 70.0% | 62.6% |
Dividend Yield | 3.0% | 0.0% | 0.0% |
Shareholder Yield | 1.5% | 1.2% | -0.6% |
1 Year Price Total Return | 8.5% | 9.8% | -11.0% |
Beta (5 Year) | 0.46 | 0.53 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Jan-23 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 79,990 | 85,159 | 88,821 | 21,395 | 22,520 |
| Operating Income | 22,181 | 23,864 | 22,601 | 4,836 | 4,088 |
| Net Profit | 17,941 | 35,153 | 14,066 | 4,049 | 3,431 |
| Diluted EPS | 6.14 | 5.20 | 5.79 | 1.49 | 1.41 |
| EBITDA | 28,510 | 30,967 | 29,940 | 6,296 | 5,984 |
| Balance Sheet | |||||
| Cash & ST Invest. | 22,281 | 22,927 | 24,522 | 22,927 | 24,522 |
| Current Assets | 55,294 | 53,495 | 55,893 | 53,495 | 55,893 |
| Total Assets | 187,378 | 167,558 | 180,104 | 167,558 | 180,104 |
| Current Liabilities | 55,802 | 46,282 | 50,321 | 46,282 | 50,321 |
| Total Liabilities | 110,574 | 98,784 | 108,614 | 98,784 | 108,614 |
| Total Equity | 76,804 | 68,774 | 71,490 | 68,774 | 71,490 |
| Total Debt | 40,742 | 30,432 | 37,834 | 30,432 | 37,834 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 21,194 | 22,791 | 24,266 | 7,863 | 6,983 |
| Cash From Investing | (12,371) | 878 | (18,599) | (1,202) | (1,320) |
| Cash From Financing | (8,871) | (15,825) | (3,132) | (4,655) | (1,340) |
| Free Cash Flow | 17,185 | 18,248 | 19,842 | 6,274 | 5,371 |